● Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Condition: Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome · Recurrent Chronic Myelomonocytic Leukemia · Sponsor: M.D. Anderson Cancer Center

PhasePhase 2

Planned participants76

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

This description comes directly from the study's public registry record.

Talk to the study team

Guillermo Garcia-Manero · 713-794-3604 · ggarciam@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04239157